Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
Giles, F J, Abruzzese, E, Rosti, G, Kim, D-W, Bhatia, R, Bosly, A, Goldberg, S, Kam, G L S, Jagasia, M, Mendrek, W, Fischer, T, Facon, T, Dünzinger, U, Marin, D, Mueller, M C, Shou, Y, Gallagher, N J, Larson, R A, Mahon, F-X, Baccarani, M, Cortes, J, Kantarjian, H M
Published in Leukemia (01.07.2010)
Published in Leukemia (01.07.2010)
Get full text
Journal Article
524P A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis
Johnson, M.L., Gort, E., Pant, S., Lolkema, M.P., Sebastian, M., Scheffler, M., Hwang, J., Dünzinger, U., Riemann, K., Kitzing, T., Jänne, P.A.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article